Cargando…
Oral etoposide combined with oral arsenic plus retinoic acid for two cases with newly diagnosed high-risk acute promyelocytic leukemia during COVID19 pandemic
Acute promyelocytic leukemia (APL) is a highly curable hematology malignancy. The major factor influence prognosis of APL is early deaths (ED) during the course of induction therapy, especially in high-risk APL. Therefore, effective reduction of white blood cells and correction of coagulation abnorm...
Autores principales: | Lu, Sheng-ye, Wen-jing, Li, Lou, Rui, Ma, Rui, Zhu, Ji-hong, Jiang, Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326808/ https://www.ncbi.nlm.nih.gov/pubmed/34367907 http://dx.doi.org/10.1016/j.lrr.2021.100258 |
Ejemplares similares
-
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia
por: Ma, Ya-Fang, et al.
Publicado: (2022) -
All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis
por: Ma, Yafang, et al.
Publicado: (2016) -
Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia
por: Lou, Yinjun, et al.
Publicado: (2021) -
Retinoic Acid and Arsenic for Treating Acute Promyelocytic Leukemia
por: Zhou, Guang-Biao, et al.
Publicado: (2005) -
Hypertriglyceridemia in Newly Diagnosed Acute Promyelocytic Leukemia
por: Sun, Jianai, et al.
Publicado: (2020)